<DOC>
	<DOCNO>NCT00314327</DOCNO>
	<brief_summary>The purpose project evaluate efficacy long-acting risperidone patient first episode schizophrenia spectrum improve sufficiently first antipsychotic medication try initial treatment trial .</brief_summary>
	<brief_title>Optimizing Response Psychosis Study</brief_title>
	<detailed_description>The goal propose pilot study investigate feasibility efficacy long-acting injectable form second generation antipsychotic , risperidone , treatment first episode patient fail respond 12 week treatment oral antipsychotic . The rationale use long-acting medication eliminate covert non-adherence , may factor poor response . In addition , pharmacokinetic pharmacodynamic difference injectable oral formulation may result difference treatment response favor injectable form . Subjects respond sufficiently treatment antipsychotic approach propose long-acting risperidone trial . Risperidone treatment open label titration base upon individual response ( within FDA approve dose range ) . Treatment begin phase supplementation oral risperidone . Subjects stop previous antipsychotic , start 2 mg oral risperidone per day one day increase dose 4 mg per day . Subjects tolerate one week oral risperidone begin injection 25 mg long-acting risperidone every 2 week total 12 week . If clinically indicate , dose may increase maximum 50 mg per FDA guideline .</detailed_description>
	<mesh_term>Disease</mesh_term>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Psychotic Disorders</mesh_term>
	<mesh_term>Mental Disorders</mesh_term>
	<mesh_term>Risperidone</mesh_term>
	<criteria>Current DSMIVdefined diagnosis schizophrenia , schizophreniform disorder , schizoaffective disorder , psychotic disorder NOS assess use Structured Clinical Interview Axis I DSMIV Disorders ( SCIDI/P ) ( First et al , 1998 ) Is first episode illness . First episode define 6 month less lifetime treatment antipsychotic . Has respond sufficiently treatment antipsychotic . Lack response define rating study entry 4 ( moderate ) least one follow BPRSA item : conceptual disorganization , grandiosity , hallucinatory behavior , unusual thought content . Continuous antipsychotic treatment time study entry minimum 12 week antipsychotic agent . Antipsychotic dose point 12 week must reach sufficient dose antipsychotic response ( e.g . patient receive low dose quetiapine insomnia anxiety would qualify ) . Sufficient dose second generation antipsychotic define minimum dose risperidone 3 mg/day , olanzapine 10 mg/day , quetiapine 500 mg/day , ziprasidone 100 mg/day aripiprazole 15 mg/day . Sufficient dose first generation antipsychotic define 3 mg/day haloperidol equivalent first generation agent . Aged 15 40 . If age 18 old , competent willing sign inform consent . If age 18 , parent guardian consent subject assent . For woman , negative urine pregnancy test agreement use medically accept method birth control . Exclusion criterion : Meets DSMIV criterion current substanceinduced psychotic disorder , psychotic disorder due general medical condition , delusional disorder , brief psychotic disorder , share psychotic disorder , mood disorder ( major depression bipolar ) psychotic feature . Persistence psychotic symptom due nonadherence antipsychotic medication . Medical contraindication treatment longacting injectable risperidone . Serious neurological endocrine disorder medical condition /treatment know affect brain . A medical condition require medication psychotropic effect . Clinical assessment trial participation contraindicate due risk homicidal suicidal behavior . A diagnosis diabetes ( fast glucose &gt; 126 mg/dl ) . Requires antidepressant mood stabilize medication . Previous treatment long act formulation antipsychotic</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>40 Years</maximum_age>
	<verification_date>June 2015</verification_date>
	<keyword>first episode</keyword>
	<keyword>schizophrenia</keyword>
	<keyword>risperidone</keyword>
</DOC>